Key Takeaways
- The ethics of conducting human trials on healthy individuals raises significant safety and effectiveness concerns.
- Influencers promoting experimental treatments may lead to unrealistic expectations among trial participants.
- Future trials may explore the therapeutic use of VEGF for conditions like baldness and erectile dysfunction.
Concerns Surrounding Human Trials
The debate surrounding the ethical implications of using healthy individuals in human trials for experimental treatments continues. Experts, such as Fernandez Lynch, emphasize that the associated risks may outweigh potential benefits for those without serious health issues. She argues that while the technology’s safety and efficacy remain in question—even for patients facing life-threatening conditions—risk exposure is significantly heightened for healthy individuals.
Conversely, others advocate for these trials. Leshko points out the high mortality rate associated with age-related causes, arguing that creating “ethical” barriers for trials on “healthy” individuals is, in fact, unethical, given the pressing need for advancements in medical science.
Biohackers and influencers like Asprey, who aims to live to 180, describe experimental substances, such as VEGF, as “longevity compounds,” suggesting they could provide significant health benefits. Eterna’s CEO, Khan, also brands the treatment as “the ultimate upgrade.” However, comments from both Asprey and Khan were not available for further clarification.
Experts, including Michael Gusmano, caution against the messaging from influencers, noting it may foster a “therapeutic misconception.” He identifies the risk that participants may hold unrealistic expectations regarding the trials’ benefits. “What you can guarantee is that the volunteers will help expand knowledge regarding how this intervention works,” he stresses.
Gusmano personally discourages anyone he knows from participating in such trials, underscoring the need for caution among the public.
Future Direction of VEGF Therapy
The current study involving VEGF therapy is just the beginning for the Unlimited Bio team, which aims to explore additional applications, including treatments for baldness and erectile dysfunction. Leshko has cited research indicating potential benefits linked to higher VEGF levels in mice, which apparently correlate to denser hair follicles. He envisions injecting VEGF therapy into the scalps of volunteers to test its efficacy.
Morgunov, who has experienced hair loss, is already experimenting with this approach personally. There are plans for a potential erectile dysfunction trial, albeit without finalized protocols. Leshko expresses enthusiasm for this idea, suggesting multiple injections might be involved.
However, not everyone shares this optimism. Ylä-Herttuala warns that hair growth is predominantly influenced by hormonal factors, and any injection procedure carries inherent risks, including potential damage to the penis in the case of erectile dysfunction treatments. Concerns also extend to the possibility of swelling at the injection site, particularly in sensitive areas.
In summary, the excitement surrounding experimental treatments like VEGF therapy must be balanced with careful consideration of potential risks and ethical standards. As research progresses, the outcomes could provide insight into the future of age-related medical interventions while illuminating crucial safety concerns.
The content above is a summary. For more details, see the source article.